WO1999058145A3 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO1999058145A3
WO1999058145A3 PCT/GB1999/001461 GB9901461W WO9958145A3 WO 1999058145 A3 WO1999058145 A3 WO 1999058145A3 GB 9901461 W GB9901461 W GB 9901461W WO 9958145 A3 WO9958145 A3 WO 9958145A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
binding
etxb
ctxb
immunomodulators
Prior art date
Application number
PCT/GB1999/001461
Other languages
English (en)
Other versions
WO1999058145A2 (fr
Inventor
Timothy Raymond Hirst
Neil Andrew Williams
Original Assignee
Univ Bristol
Timothy Raymond Hirst
Neil Andrew Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809958.3A external-priority patent/GB9809958D0/en
Priority claimed from GBGB9812316.9A external-priority patent/GB9812316D0/en
Priority to PL34451999A priority Critical patent/PL344519A1/xx
Priority to HU0104842A priority patent/HUP0104842A3/hu
Priority to CA 2331832 priority patent/CA2331832A1/fr
Priority to US09/674,935 priority patent/US7914791B1/en
Priority to AU39394/99A priority patent/AU3939499A/en
Priority to NZ507911A priority patent/NZ507911A/en
Priority to JP2000547996A priority patent/JP4666761B2/ja
Priority to BR9910305A priority patent/BR9910305A/pt
Application filed by Univ Bristol, Timothy Raymond Hirst, Neil Andrew Williams filed Critical Univ Bristol
Priority to GB0027072A priority patent/GB2353472A/en
Priority to MXPA00010934A priority patent/MXPA00010934A/es
Priority to EP19990922284 priority patent/EP1075274A2/fr
Priority to EA200001134A priority patent/EA004794B1/ru
Priority to KR1020007012486A priority patent/KR20010043441A/ko
Publication of WO1999058145A2 publication Critical patent/WO1999058145A2/fr
Publication of WO1999058145A3 publication Critical patent/WO1999058145A3/fr
Priority to IS5694A priority patent/IS5694A/is
Priority to IL139467A priority patent/IL139467A/en
Priority to NO20005599A priority patent/NO20005599L/no
Priority to AU2003261492A priority patent/AU2003261492B2/en
Priority to US13/038,021 priority patent/US20110223194A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation (i) de EtxB, CtxB ou de VtxB exempt de toute toxine, (ii) d'un agent autre que EtxB ou CtxB ayant une activité de liaison GM1, ou d'un agent autre que VtxB ayant une activité de liaison Gb3, ou (iii) d'un agent ayant un effet sur des événements de transmission de signaux intracellulaires dont la médiation est assurée par liaison GM1 ou Gb3, comme immunomodulateur pour un vaccin contre des maladies infectieuses.
PCT/GB1999/001461 1998-05-08 1999-05-10 Vaccin WO1999058145A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EA200001134A EA004794B1 (ru) 1998-05-08 1999-05-10 Вакцина
KR1020007012486A KR20010043441A (ko) 1998-05-08 1999-05-10 백신용 면역조절제
EP19990922284 EP1075274A2 (fr) 1998-05-08 1999-05-10 Vaccin
CA 2331832 CA2331832A1 (fr) 1998-05-08 1999-05-10 Sous-unite b d'enterotoxine thermolabile d'e. coli (etxb) en tant qu'immunomodulateur
US09/674,935 US7914791B1 (en) 1998-05-08 1999-05-10 Vaccine
AU39394/99A AU3939499A (en) 1998-05-08 1999-05-10 Vaccine
NZ507911A NZ507911A (en) 1998-05-08 1999-05-10 Immunomodulators for vaccines
JP2000547996A JP4666761B2 (ja) 1998-05-08 1999-05-10 ワクチンのための免疫調節因子
BR9910305A BR9910305A (pt) 1998-05-08 1999-05-10 Vacina
PL34451999A PL344519A1 (en) 1998-05-08 1999-05-10 Vaccine
GB0027072A GB2353472A (en) 1998-05-08 1999-05-10 Vaccine
MXPA00010934A MXPA00010934A (es) 1998-05-08 1999-05-10 Vacuna.
HU0104842A HUP0104842A3 (en) 1998-05-08 1999-05-10 Vaccine
IS5694A IS5694A (is) 1998-05-08 2000-10-31 Bóluefni
IL139467A IL139467A (en) 1998-05-08 2000-11-05 USE OF EtxB, CtxB OR VtxB IN THE MANUFACTURE OF A VACCINE AGAINST INFECTIOUS DISEASES
NO20005599A NO20005599L (no) 1998-05-08 2000-11-06 Vaksine
AU2003261492A AU2003261492B2 (en) 1998-05-08 2003-11-07 Vaccine
US13/038,021 US20110223194A1 (en) 1998-05-08 2011-03-01 Vaccine

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9809958.3 1998-05-08
GBGB9809958.3A GB9809958D0 (en) 1998-05-08 1998-05-08 Vaccine
GB9811954.8 1998-06-03
GBGB9811954.8A GB9811954D0 (en) 1998-05-08 1998-06-03 Vaccine
GBGB9812316.9A GB9812316D0 (en) 1998-06-08 1998-06-08 Cancer vaccines
GB9812316.9 1998-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/038,021 Division US20110223194A1 (en) 1998-05-08 2011-03-01 Vaccine

Publications (2)

Publication Number Publication Date
WO1999058145A2 WO1999058145A2 (fr) 1999-11-18
WO1999058145A3 true WO1999058145A3 (fr) 2000-02-03

Family

ID=27269307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001461 WO1999058145A2 (fr) 1998-05-08 1999-05-10 Vaccin

Country Status (18)

Country Link
EP (1) EP1075274A2 (fr)
JP (1) JP4666761B2 (fr)
KR (1) KR20070067719A (fr)
CN (1) CN100335130C (fr)
AU (1) AU3939499A (fr)
BR (1) BR9910305A (fr)
CA (1) CA2331832A1 (fr)
CZ (1) CZ302333B6 (fr)
EA (1) EA004794B1 (fr)
GB (1) GB2353472A (fr)
HU (1) HUP0104842A3 (fr)
IL (1) IL139467A (fr)
IS (1) IS5694A (fr)
MX (1) MXPA00010934A (fr)
NO (1) NO20005599L (fr)
NZ (1) NZ507911A (fr)
PL (1) PL344519A1 (fr)
WO (1) WO1999058145A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB0030067D0 (en) * 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
GB0115382D0 (en) * 2001-06-22 2001-08-15 Univ Bristol Mutant
CN111100824B (zh) * 2020-01-21 2021-11-05 暨南大学 一株芽孢杆菌及其在养殖水体中脱氮除硫的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372928A2 (fr) * 1988-12-07 1990-06-13 University Of Leicester Protéines de fusion de la sous-unité B de la toxine labile à la chaleur
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
WO1997002045A1 (fr) * 1995-07-05 1997-01-23 Oratol Limited Agents therapeutiques pour maladies auto-immunes
EP0919243A1 (fr) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccin dont l'adjuvant est constitué de sous-unités B de l'entérotoxine thermolabile (LTB) d'Escherichia coli
WO1999036088A1 (fr) * 1998-01-16 1999-07-22 Maxim Pharmaceuticals, Inc. Vaccins recombines a partir de la sous-unite b de la toxine cholerique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372928A2 (fr) * 1988-12-07 1990-06-13 University Of Leicester Protéines de fusion de la sous-unité B de la toxine labile à la chaleur
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
WO1997002045A1 (fr) * 1995-07-05 1997-01-23 Oratol Limited Agents therapeutiques pour maladies auto-immunes
EP0919243A1 (fr) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccin dont l'adjuvant est constitué de sous-unités B de l'entérotoxine thermolabile (LTB) d'Escherichia coli
WO1999036088A1 (fr) * 1998-01-16 1999-07-22 Maxim Pharmaceuticals, Inc. Vaccins recombines a partir de la sous-unite b de la toxine cholerique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIRST T R ET AL: "Cholera toxin and related enterotoxins as potent immune modulators.", SOCIETY FOR APPLIED BACTERIOLOGY SYMPOSIUM SERIES, (1998) 27 26S-34S, XP000856429 *
NASHAR T O ET AL: "Importance of receptor binding in the immunogenicity, adjuvanticity and therapeutic properties of cholera toxin and Escherichia coli heat-labile enterotoxin.", MEDICAL MICROBIOLOGY AND IMMUNOLOGY, (1998 JUN) 187 (1) 3-10, XP000857029 *
NASHAR T O ET AL: "Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1.", IMMUNOLOGY, (1997 AUG) 91 (4) 572-8., XP002123821 *
RICHARDS C M ET AL: "Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency.", JOURNAL OF INFECTIOUS DISEASES, (1998 JUN) 177 (6) 1451-7., XP002123823 *
WILLIAMS N A ET AL: "Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.", IMMUNOLOGY TODAY, (1999 FEB) 20 (2) 95-101, XP002123822 *
ZHANG T ET AL: "ORAL IMMUNIZATION WITH THE DODECAPEPTIDE REPEAT OF THE SERINE-RICH ENTAMOEBA HISTOLYTICA PROTEIN (SREHP) FUSED TO THE CHOLERA TOXIN B SUBUNIT INDUCES A MUCOSAL AND SYSTEMIC ANTI-SREHP ANTIBODY RESPONSE", INFECTION AND IMMUNITY,US,AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 63, no. 4, pages 1349-1355, XP000645273, ISSN: 0019-9567 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine

Also Published As

Publication number Publication date
NO20005599L (no) 2001-01-08
EA004794B1 (ru) 2004-08-26
NO20005599D0 (no) 2000-11-06
BR9910305A (pt) 2001-01-09
IL139467A0 (en) 2001-11-25
HUP0104842A2 (hu) 2002-04-29
CZ302333B6 (cs) 2011-03-16
WO1999058145A2 (fr) 1999-11-18
IL139467A (en) 2011-11-30
EA200001134A1 (ru) 2001-08-27
CN1308546A (zh) 2001-08-15
KR20070067719A (ko) 2007-06-28
CN100335130C (zh) 2007-09-05
MXPA00010934A (es) 2003-07-14
JP2002514607A (ja) 2002-05-21
CA2331832A1 (fr) 1999-11-18
HUP0104842A3 (en) 2002-12-28
GB0027072D0 (en) 2000-12-20
GB2353472A (en) 2001-02-28
IS5694A (is) 2000-10-31
JP4666761B2 (ja) 2011-04-06
CZ20004147A3 (en) 2001-05-16
NZ507911A (en) 2004-04-30
EP1075274A2 (fr) 2001-02-14
PL344519A1 (en) 2001-11-05
AU3939499A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
WO2004060308A3 (fr) Thiosemicarbazones antiviraux et immunostimulants
WO2000002987A3 (fr) Composes de reaction d'amine contenant un ou plusieurs ingredients actifs
WO2002002525A3 (fr) N-ureidoheterocycloaklyl-piperidines utilises comme modulateurs de l'activite du recepteur de la chimiokine
EP1293503A4 (fr) Derives de triazole
AU5242000A (en) Nematicidal trifluorobutenes
ZA200110479B (en) Respiratory syncytial virus replication inhibitors.
WO2002053516A3 (fr) Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
ZA200110473B (en) Respiratory syncytial virus replication inhibitors.
EP1283058A4 (fr) Agents permettant de prevenir ou d'ameliorer l'insulino-resistance et/ou l'obesite
EP0630898A4 (fr) Remede contre la thrombopenie.
WO1999058145A3 (fr) Vaccin
AR029590A1 (es) Antibacterianos
WO2001098270A3 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
EP0832875A4 (fr) Inhibiteur des metalloproteinases, tres soluble dans l'eau
AU1817902A (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
WO2001098269A3 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
EP1426360A4 (fr) Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
EP1076057A4 (fr) Febrifugine et isofebrifugine, et leurs procedes de preparation
EP1026162A4 (fr) Agent anti-rhumatismal
AU6724500A (en) Motorcyclist suit
EP1270572A4 (fr) Derives de pyrazole condense, procede de production et utilisation
WO2001007087A8 (fr) Agents therapeutiques anti-infectieux catalyses par des enzymes
WO2001083518A3 (fr) Molecules qui modulent la proteolyse dependant de l'ubiquitine et procedes d'identification de ces molecules
AU1877399A (en) Bicyclene substituted by an aminocarbonyl radical, the production and use thereof as a medicament
IL152632A0 (en) Trimethyldecenyl compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808403.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000/06160

Country of ref document: ZA

Ref document number: 200006160

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 507911

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 200027072

Country of ref document: GB

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00589/MU

Country of ref document: IN

Ref document number: 39394/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2331832

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/010934

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2000-4147

Country of ref document: CZ

Ref document number: P-691/00

Country of ref document: YU

Ref document number: 1020007012486

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200001134

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1999922284

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09674935

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999922284

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-4147

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007012486

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020007012486

Country of ref document: KR